Santhera Pharmaceuticals has signed an exclusive distribution agreement with Genesis Pharma for Agamree.
The therapeutic, otherwise called vamorolone, will be used to treat patients with Duchenne muscular dystrophy (DMD).
It will be available to patients in 20 markets across Central and Eastern Europe, significantly bolstering the global availability of the drug.
Vamorolone is a dissociative anti-inflammatory drug that can be an efficacious alternative to the current standard of care treatment for DMD: corticosteroids.
Young patients taking corticosteroids regularly can face growth stunting, but Agamree does not exhibit this effect.
Following the pivotal regulatory decision by the European Commission to approve Agamree in December 2023, Santhera has been making active efforts to boost the global reach of the therapeutic.
Santhera's CCO, Geert Jan van Daal, commented: “This distribution agreement with GENESIS Pharma marks a significant achievement for Santhera as we expand the global availability of AGAMREE. By partnering with expert organizations with a strong understanding of specialist markets, we ensure optimal patient access,”
“This is a further step in our strategy to allow focus on key European markets with dedicated Santhera teams while partnering with the best companies for non-core European markets.”
Constantinos Evripides, Managing Director of Genesis Pharma, stated: “Our company has a strong focus on rare diseases and an established expertise of more than 20 years in the commercialisation of orphan therapies."
"We are delighted that Santhera has trusted our capabilities across the CEE region, giving us the opportunity to add Vamorolone to our broad and robust orphans’ portfolio. We will work closely and diligently with Santhera to ensure a smooth and unhindered access to all patients that can benefit from this innovative treatment.”
